Taming the beast

Even as the hedge fund industry gears up for an expected new push by US regulators to register with the Securities and Exchange Commission (SEC), new rules targeting over-the-counter derivatives markets could have just as significant an impact on how hedge funds and investment managers do business, and which technologies they'll need to do so.

No doubt buy-side firms would like to know exactly how a new regulatory regime for OTC derivatives would affect them operationally, but although more

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: